Biodesix, Inc.

Nasdaq : BDSX

Предоставляет диагностические тесты и услуги при заболеваниях легких.

  • Filed 02-10-2020
  • Set Terms --
  • IPO Date 28-10-2020
  • Lock Up 27-01-2021
Текущая цена
5.26 $
Текущая доходность
-70.78 %
Доходность за 1 день торгов
-28.83 %
Доходность по итогам
Lock up периода
22 %
Рейтинг от
Дата IPO
Объем размещения
4 000 000
Размер сделки ($M)
Диапазон цены
17-19 $
Цена IPO
18 $
Lock Up
Год основания
Головной офис
Boulder, CO
Веб сайт
Davis Polk Sidley Austin
Morgan Stanley

Описание компании

We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient’s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient’s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex®, to discover innovative diagnostic tests for clinical use.